Exact Sciences (NASDAQ:EXAS) is a molecular diagnostics company focused on the early detection and prevention of cancer. Founded in 1995 and headquartered in Madison, Wisconsin, the company developed Cologuard, the first noninvasive, stool-based DNA screening test for colorectal cancer approved by the U.S. Food and Drug Administration. Cologuard combines DNA and hemoglobin biomarkers to detect cancerous and precancerous lesions, offering an alternative to traditional colonoscopy for average-risk patients.
In addition to its flagship colorectal cancer test, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research. The acquisition of Genomic Health in 2019 extended the company’s precision oncology offerings by bringing Oncotype DX tests for breast, prostate and other cancers under its umbrella. These genomic assays analyze tumor biology to guide treatment decisions, helping oncologists personalize therapy and avoid unnecessary treatments.
Exact Sciences serves patients and healthcare providers across the United States and has begun international expansion into Europe, Canada and select Latin American markets. The company works closely with health systems, payers and advocacy organizations to increase adoption of its tests and integrate digital solutions for patient education and physician reporting. By building partnerships with research institutions, Exact Sciences also seeks to identify novel biomarkers and develop next-generation screening technologies.
Under the leadership of President and CEO Kevin Conroy, Exact Sciences has emphasized a collaborative culture that unites diagnostics, research and commercial expertise. The management team includes executives with backgrounds in biotechnology, genomics and health economics, driving efforts to improve screening rates and advance the company’s pipeline of liquid biopsy tests for multiple cancer types. Exact Sciences continues to invest in innovation and scale its operations with the goal of transforming cancer detection and patient outcomes worldwide.
